

Title (en)

NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM

Title (de)

NICHT-PEPTIDISCHE GNRH-AGENZIEEN, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND METHODEN ZU IHRER VERWENDUNG SOWIE VERFAHREN ZU IHRER HERSTELLUNG

Title (fr)

AGENTS GNRH NON PEPTIDIQUES, COMPOSITIONS PHARMACEUTIQUES ET METHODES D'UTILISATION DE CES DERNIERES, PROCEDES DE PREPARATION DE CES COMPOSES

Publication

EP 1401427 A4 20041201 (EN)

Application

EP 02739712 A 20020605

Priority

- US 0217846 W 20020605
- US 29581201 P 20010606
- US 30186801 P 20010629

Abstract (en)

[origin: WO02098363A2] Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

IPC 1-7

A61K 31/341; **A61K 31/443**; **A61K 31/497**; **C07D 307/58**; **C07D 405/10**; **C07D 405/12**; **C07D 405/14**; **C07D 307/68**; **A61P 15/00**; **A61P 35/00**

IPC 8 full level

A61K 31/341 (2006.01); **A61K 31/343** (2006.01); **A61K 31/353** (2006.01); **A61K 31/404** (2006.01); **A61K 31/41** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/437** (2006.01); **A61K 31/443** (2006.01); **A61K 31/4525** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/506** (2006.01); **A61K 31/5377** (2006.01); **A61P 5/24** (2006.01); **A61P 15/00** (2006.01); **A61P 25/00** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01); **C07D 307/68** (2006.01); **C07D 307/87** (2006.01); **C07D 307/91** (2006.01); **C07D 405/12** (2006.01); **C07D 405/14** (2006.01); **C07D 407/12** (2006.01); **C07D 471/04** (2006.01); **C07D 493/10** (2006.01); **C07D 521/00** (2006.01)

CPC (source: EP)

A61P 5/02 (2017.12); **A61P 5/24** (2017.12); **A61P 15/00** (2017.12); **A61P 25/00** (2017.12); **A61P 31/12** (2017.12); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **A61P 43/00** (2017.12); **C07D 231/12** (2013.01); **C07D 233/56** (2013.01); **C07D 249/08** (2013.01); **C07D 307/68** (2013.01); **C07D 405/12** (2013.01); **C07D 405/14** (2013.01); **C07D 407/12** (2013.01); **C07D 471/04** (2013.01)

Citation (search report)

- [DA] WO 0020358 A2 20000413 - AGOURON PHARMA [US], et al
- [DA] WO 9944987 A1 19990910 - ALANEX CORP [US]
- See references of WO 02098363A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02098363 A2 20021212; **WO 02098363 A3 20030320**; AU 2002312348 A1 20021216; BR 0210191 A 20040406; CA 2449843 A1 20021212; EP 1401427 A2 20040331; EP 1401427 A4 20041201; JP 2005501006 A 20050113; MX PA03011002 A 20041028

DOCDB simple family (application)

US 0217846 W 20020605; AU 2002312348 A 20020605; BR 0210191 A 20020605; CA 2449843 A 20020605; EP 02739712 A 20020605; JP 2003501405 A 20020605; MX PA03011002 A 20020605